Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Advanced Medical Solutions Group Cash-to-Debt?
Advanced Medical Solutions GroupCHIX:AMSL +0.18%78 Cash-to-Debt is 0.22 as of Dec. 2025, which is 97% below its 10-year median of 6.42. GuruFocus rates CHIX:AMSL with a GF Score™ of 78/100 and a GF Value™ of £3.76 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 82.66% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Advanced Medical Solutions Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.22.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Advanced Medical Solutions Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Advanced Medical Solutions Group's Cash-to-Debt or its related term are showing as below:
CHIX:AMSl'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2 Med: 6.42 Max: No Debt
Current: 0.22
During the past 13 years, Advanced Medical Solutions Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.20. And the median was 6.42.
CHIX:AMSl's Cash-to-Debt is ranked worse than 82.66% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs CHIX:AMSl: 0.22
Advanced Medical Solutions Group (CHIX:AMSl) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Advanced Medical Solutions Group Cash-to-Debt Related Terms
Advanced Medical Solutions Group Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Advanced Medical Solutions Group Cash-to-Debt Chart
CHIX:AMSL vs ISRG, BDX, RMD: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a Cash-to-Debt of 0.22 as of Dec. 2025. This is 97% below median its historical median of 6.42. Over the past decade, Advanced Medical Solutions Group's Cash-to-Debt has ranged from 0.20 to 10,000.00. According to the industry distribution chart, Advanced Medical Solutions Group ranks #696 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 82.7%.
Is Advanced Medical Solutions Group's Cash-to-Debt too high?
Advanced Medical Solutions Group's current Cash-to-Debt of 0.22 is 97% below median its 10-year median of 6.42. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. Advanced Medical Solutions Group's value of 0.22 is 86.3% below this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #696 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Advanced Medical Solutions Group has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #696 out of 842 companies for Cash-to-Debt. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Cash-to-Debt is 1.61. Advanced Medical Solutions Group's value of 0.22 is 86.3% below this benchmark. Historically, Advanced Medical Solutions Group's own Cash-to-Debt has ranged from 0.20 to 10,000.00 over the past decade. While the company's 10-year median is 6.42 vs. the industry median of 1.61, Advanced Medical Solutions Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current Cash-to-Debt of 0.22 is 86.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Cash-to-Debt is 0.22, which is 97% below median its own 10-year median of 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.76, compared to a current price of £2.82 — trading 25.1% below its estimated fair value. The current Cash-to-Debt is 0.22, which is 97% below median its 10-year median of 6.42 and 86.3% below the Medical Devices & Instruments industry median of 1.61. Advanced Medical Solutions Group's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Cash-to-Debt is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.82 is trading 25.1% below its estimated GF Value™ of £3.76.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Cash-to-Debt: 0.22 (97% below median its 10-year median of 6.42)
GF Value™: £3.76 vs. price of £2.82 (25.1% below fair value)
Industry Position: 86.3% below the Medical Devices & Instruments median (#696 of 842)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
78GF Score
Get the complete analysis for CHIX:AMSL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
